Australian-Singaporean regenerative medicine company Osteopore (ASX:OSX) has announced that it has secured market approval for its orthopaedic products in Singapore and Vietnam.
-
Latest News Osteopore announces Singapore and Vietnam market approvals March 28, 2024
-
Latest News CSL prices US$1.25 billion in new corporate bonds March 28, 2024CSL (ASX:CSL) has announced that it has priced US$1.25 billion in corporate bonds in the US market.
-
Latest News Clarity Pharmaceuticals launches $121 million fully underwritten equity raising March 26, 2024Australian clinical-stage radiopharmaceutical company Clarity Pharmaceuticals (ASX:CU6) has announced a fully underwritten $121 million equity raising comprising a pro-rata accelerated non-renounceable entitlement offer and placement to institutional investors.
-
AusBiotech Sector invited to support national strategy for non-animal research models March 26, 2024Australia’s life science ecosystem is invited to join AusBiotech in supporting Australian Ethical’s statement supporting non-animal research models as and call on the government to implement a national strategy.
-
Latest News 'Reaching this point in the development of bisantrene is a major milestone and accomplishment' March 26, 2024Race Oncology (ASX:RAC) has announced that a Certificate of Analysis has been issued for the first current Good Manufacturing Practice batch of its proprietary bisantrene formulation, RC220.
-
Latest News Cicada Innovations launches HealthTech Hub in Sydney’s 'hidden innovation ecosystem' March 26, 2024The facility, supported by a grant from Investment NSW, will be situated in Sydney's Western Suburbs, within one of Australia's largest health and biomedical precincts, the Westmead Health and Innovation District.
-
Latest News Orthocell completes all nerve repair surgeries in Remplir US market authorisation study March 26, 2024Australian regenerative medicine company Orthocell (ASX:OCC) has announced it has completed the first stage of the Remplir US 510(k) market authorisation nerve repair study.
-
Latest News Cochlear announces the resignation of non-executive director Yasmin Allen AM March 26, 2024Cochlear (ASX:COH) has announced that Yasmin Allen AM is resigning from its board as an independent non-executive director.
-
Latest News Rhythm Biosciences establishes internationally renowned clinical advisory board March 20, 2024“We are honoured to have world-class, distinguished leaders in their field of Colorectal Cancer diagnostics form our CAB and look forward to their expertise and guidance in this significant commercialisation stage of ColoSTAT,” said Otto Buttula, executive chairman of Rhythm.
-
AusBiotech Cell & Gene Catalyst submits feedback on HTA consultation March 21, 2024Australia’s Cell & Gene Catalyst (the Catalyst) has called for streamlined and equitable access for cell and gene (C&G) therapies in Australia in its response to the Department of Health and Aged Care’s Health Technology Assessment (HTA) Policy and Methods Review - Consultation 2.
-
Latest News LTR Pharma says first patient, first dose in the SPONTAN pivotal clinical study March 20, 2024LTR Pharma (ASX:LTP) has announced that the first patients have completed the first dosing in its pivotal bioequivalence clinical study of SPONTAN nasal spray.
-
Latest News Gut microbiome and gene editing projects share in $3 million research funding March 21, 2024The Dementia Australia Research Foundation has announced funding for 24 projects worth more than $3 million in total.
-
Latest News Applications open for Moderna's 2024 Australia Fellowship Program March 20, 2024"Last year, we were delighted with the calibre of applicants and witnessed the remarkable potential of Australian researchers to contribute to the field of mRNA medicine," said Dr Craig Rayner, director of Moderna's Regional Research Centre for Respiratory Medicines and Tropical Diseases.
-
Latest News PYC Therapeutics announces the completion of institutional placement March 19, 2024PYC Therapeutics (ASX:PYC) has announced the successful closure of the institutional component of the entitlement offer to raise up to approximately $74.6 million.
-
AusBiotech Queensland’s biomedical grant programme opens March 19, 2024Queensland-based biomedical companies, universities and research institutes are invited to apply for the Queensland Biomedical Business Attraction Program’s latest funding round.
-
Latest News CSIRO announces the appointment of new Australian Centre for Disease Preparedness director March 19, 2024Australia’s national science agency, CSIRO, has announced Dr Debbie Eagles’ appointment to director of the Australian Centre for Disease Preparedness.
-
Latest News Telix announces QDOSE platform partnership for personalised dosimetry in radiopharmaceutical the March 19, 2024Telix has entered into an agreement to commercially partner the QDOSE dosimetry software platform with Germany-based contract research organisation Advanced Pharmaceutical Services Forschungsgesellschaft and its partner, Stockholm-based Quantinm.
New Stories
-
AusMedtech 2024 programme launched
March 28, 2024 - - AusBiotech -
Clarity successfully completes placement and institutional entitlement offer
March 28, 2024 - - Latest News -
Osteopore announces Singapore and Vietnam market approvals
March 28, 2024 - - Latest News -
CSL prices US$1.25 billion in new corporate bonds
March 28, 2024 - - Latest News -
Amplia Therapeutics updates on next stage of ACCENT pancreatic cancer trial
March 28, 2024 - - Latest News -
Clarity Pharmaceuticals launches $121 million fully underwritten equity raising
March 26, 2024 - - Latest News -
Sector invited to support national strategy for non-animal research models
March 26, 2024 - - AusBiotech